Pneumology - Original Articles
30 July 2025
Early Access
https://doi.org/10.4081/monaldi.2025.3433

Evaluating hematological and inflammatory biomarkers in tuberculosis management

Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
Tuberculosis, inflammatory biomarkers, C-reactive protein, anemia in TB, hematological markers
138
Views
81
Downloads

Authors

Sanatkumar Bharamu Nyamagoud
https://orcid.org/0000-0002-5111-7685
Department of Pharmacy Practice, KLE College of Pharmacy, Vidyanagar, Hubballi, Karnataka, India.
Princy Domnic Dsouza
princydsouza1012@gmail.com
Department of Pharmacy Practice, KLE College of Pharmacy, Vidyanagar, Hubballi, Karnataka, India.
Sai Phalguna Prakash Chitralu
Department of Pharmacy Practice, KLE College of Pharmacy, Vidyanagar, Hubballi, Karnataka, India.
Kadambari Solankure
https://orcid.org/0000-0002-3740-6931
Department of Kriya Sharir Kaher’s Shri B M Kankanwadi Ayurveda Mahavidyalaya Shahapur, Belagavi, Karnataka, India.
Agadi Hiremath Viswanatha Swamy
Department of Pharmacy Practice, KLE College of Pharmacy, Vidyanagar, Hubballi, Karnataka, India.

Tuberculosis (TB) remains a significant public health concern, particularly in resource-limited settings. Accurate and timely diagnosis and effective monitoring of disease progression and treatment response remain a challenge. This research aims to evaluate the function of hematological and inflammatory biomarkers, including hemoglobin (HB), serum amyloid A (SAA), C-reactive protein (CRP), erythrocyte sedimentation rate (ESR), and white blood cell (WBC) count, in TB patients. Overall, 80 TB patients were analyzed to evaluate the association of these biomarkers with disease status and demographic characteristics. The findings revealed significant alterations in inflammatory markers, with elevated WBC, SAA, CRP, and ESR levels, indicating an ongoing inflammatory response. Additionally, decreased HB levels were observed, suggesting the presence of anemia, which is commonly associated with chronic infections such as TB. Pearson's correlation analysis revealed a significant negative connection between HB and inflammatory markers, reinforcing the link between anemia and TB-associated inflammation. However, no noteworthy associations were found between biomarker levels and demographic parameters, including age and gender, residence, or treatment duration. These findings emphasize the potential utility of these biomarkers in TB diagnosis, prognosis, and treatment monitoring, especially in regions where advanced diagnostic tools are not readily available. The study suggests that routine hematological and inflammatory markers can serve as cost-effective adjunctive tools in TB administration. Additional investigation is needed to confirm these results and determine their role in predicting treatment outcomes and disease severity.

Altmetrics

Downloads

Download data is not yet available.

Citations

Crossref
Scopus
Google Scholar
Europe PMC
Kyu HH, Ledesma JR, Murray CJL. The global burden of disease study tuberculosis estimates from the Institute for Health Metrics and Evaluation. Int J Epidemiol 2024;53:dyae122. DOI: https://doi.org/10.1093/ije/dyae122
Dodd PJ, McQuaid CF, Rao P et al. Improving the quality of the global burden of disease tuberculosis estimates from the Institute for Health Metrics and Evaluation. Int J Epidemiol 2023;52:1681-6. DOI: https://doi.org/10.1093/ije/dyad128
Nogueira BMF, Krishnan S, Barreto-Duarte B, et al. Diagnostic biomarkers for active tuberculosis: progress and challenges. EMBO Mol Med 2022;14:e14088. DOI: https://doi.org/10.15252/emmm.202114088
Sutherland JS, van der Spuy G, Gindeh A, et al. Diagnostic accuracy of the Cepheid 3-gene host response fingerstick blood test in a prospective, multi-site study: interim results. Clin Infect Dis 2022;74:2136-41. DOI: https://doi.org/10.1093/cid/ciab839
Leo S, Narasimhan M, Rathinam S, Banerjee A. Biomarkers in diagnosing and therapeutic monitoring of tuberculosis: a review. Ann Med 2024;56:2386030. DOI: https://doi.org/10.1080/07853890.2024.2386030
Chegou NN, Heyckendorf J, Walzl G, et al. Beyond the IFN-γ horizon: biomarkers for immunodiagnosis of infection with Mycobacterium tuberculosis. Eur Respir J 2014;43:1472-86. DOI: https://doi.org/10.1183/09031936.00151413
López-González JA, Martínez-Soto JM, Avila-Cervantes C, et al. Evaluation of systemic inflammation before and after standard anti-tuberculosis treatment in patients with active pulmonary tuberculosis and diabetes mellitus. Cureus 2024;16:e55391. DOI: https://doi.org/10.7759/cureus.55391
Yong YK, Tan HY, Saeidi A, et al. Immune biomarkers for diagnosis and treatment monitoring of tuberculosis: current developments and future prospects. Front Microbiol 2019;10:2789. DOI: https://doi.org/10.3389/fmicb.2019.02789
Ayalew S, Wegayehu T, Wondale B, et al. Candidate serum protein biomarkers for active pulmonary tuberculosis diagnosis in tuberculosis endemic settings. BMC Infect Dis 2024;24:1329. DOI: https://doi.org/10.1186/s12879-024-10224-3
Rohini K, Surekha Bhat M, Srikumar PS, et al. Assessment of hematological parameters in pulmonary tuberculosis patients. Indian J Clin Biochem 2016;31:332-5. DOI: https://doi.org/10.1007/s12291-015-0535-8
Yoon NB, Son C, Um SJ. Role of the neutrophil-lymphocyte count ratio in the differential diagnosis between pulmonary tuberculosis and bacterial community-acquired pneumonia. Ann Lab Med 2013;33:105-10. DOI: https://doi.org/10.3343/alm.2013.33.2.105
Isanaka S, Mugusi F, Urassa W, et al. Iron deficiency and anemia predict mortality in patients with tuberculosis. J Nutr 2012;142:350-7. DOI: https://doi.org/10.3945/jn.111.144287
Minchella PA, Donkor S, Owolabi O, et al. Complex anemia in tuberculosis: the need to consider causes and timing when designing interventions. Clin Infect Dis 2015;60:764-72. DOI: https://doi.org/10.1093/cid/ciu945
Liu QY, Han F, Pan LP, et al. Inflammation responses in patients with pulmonary tuberculosis in an intensive care unit. Exp Ther Med 2018;15:2719-26. DOI: https://doi.org/10.3892/etm.2018.5775
Kerkhoff AD, Wood R, Cobelens FG, et al. The predictive value of current haemoglobin levels for incident tuberculosis and/or mortality during long-term antiretroviral therapy in South Africa: a cohort study. BMC Med 2015;13:70. DOI: https://doi.org/10.1186/s12916-015-0320-9
Sia JK, Georgieva M, Rengarajan J. Innate immune defenses in human tuberculosis: an overview of the interactions between Mycobacterium tuberculosis and innate immune cells. J Immunol Res 2015;2015:747543. DOI: https://doi.org/10.1155/2015/747543
Gupta A, Kaul A, Tsolaki AG, et al. Mycobacterium tuberculosis: immune evasion, latency and reactivation. Immunobiology 2012;217:363-74. DOI: https://doi.org/10.1016/j.imbio.2011.07.008
Lawn SD, Zumla AI. Diagnosis of extrapulmonary tuberculosis using the Xpert® MTB/RIF assay. Expert Rev Anti Infect Ther 2012;10:631-5. DOI: https://doi.org/10.1586/eri.12.43
Dheda K, Barry CE 3rd, Maartens G. Tuberculosis. Lancet 2016;387:1211-26. DOI: https://doi.org/10.1016/S0140-6736(15)00151-8

Ethics approval

The study's objectives were thoroughly explained to the patients and their families to ensure a clear understanding. KLE College of Pharmacy Ethical Committee granted ethical approval for the study (IEC Reference Number: KLECOPH/IEC/2024-25/08).

How to Cite



“Evaluating Hematological and Inflammatory Biomarkers in Tuberculosis Management”. 2025. Monaldi Archives for Chest Disease, July. https://doi.org/10.4081/monaldi.2025.3433.
Copyright (c) 2025 The Author(s) Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.